AAA Redox receives $45m in series D funding

Redox receives $45m in series D funding

Redox, a US-based healthcare data integration software developer that counts care provider Intermountain Healthcare has an investor, raised $45m yesterday in a series D round led by investment manager Adams Street Partners.

The round also featured investment firm Avenir and venture capital firms Battery Ventures, .406 Ventures and RRE Ventures.

Founded in 2014, Redox has developed a software platform that enables healthcare organisations to share patient record data efficiently and securely. The proceeds from the round will support product development and the hiring of new talent.

The company has received $95m of funding to date, having secured $33m in an April 2019 series C round led by Battery Ventures that also featured Intermountain Healthcare Innovation Fund, an investment vehicle for Intermountain, as well as .406 Ventures and RRE Ventures.

Intermountain Healthcare Innovation Fund had already provided $1m for the company’s $10m series B round in 2017. That round was led by RRE Ventures and included Dreamit Ventures and existing backers HealthX Ventures, .406 Ventures and Flybridge Capital Partners.